NASDAQ:LIMN Liminatus Pharma Q2 2025 Earnings Results & Report $2.51 -0.30 (-10.68%) Closing price 11/20/2026 04:00 PM EasternExtended Trading$2.68 +0.17 (+6.77%) As of 11/20/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Liminatus Pharma reported Q2 2025 earnings on October 4, 2025. The company reported EPS of -$2.50. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ2 2025Report DateOctober 4, 2025TimeAfter Market Closes Liminatus Pharma EPS ResultsActual EPS-$2.50Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/ALiminatus Pharma Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesEarnings HistoryCompany Profile Liminatus Pharma Q2 2025 Earnings FAQ Did Liminatus Pharma beat earnings estimates for Q2 2025? Liminatus Pharma (NASDAQ:LIMN) reported earnings of -$2.50 per share for Q2 2025. The report was announced on Saturday, October 4, 2025. Liminatus Pharma Earnings HeadlinesLiminatus Pharma (NASDAQ:LIMN) Stock Jumps 7.9% - Still a Buy?November 14, 2026 | americanbankingnews.comLiminatus Pharma Regains Nasdaq Compliance Following 1-For-50 Reverse SplitSeptember 30, 2026 | rttnews.comWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indicator for a single $7 payment. Others previously paid $500. The indicator flashes a Crash Alert as a cue to exit or go short, and a Bull Run Alert as a cue to buy or go long. No strings attached, and Wood says there is an unusual reason behind the steep discount.November 21 at 1:00 AM | Base Camp Trading (Ad)Liminatus Pharma regains NASDAQ complianceSeptember 29, 2026 | msn.comLiminatus Pharma Regains Compliance with Nasdaq Minimum Bid Price RuleSeptember 29, 2026 | globenewswire.comLiminatus Pharma Engages Synex as Contract Research Organization to Support Phase 1/2a Clinical Development of CD19xCD22 bivalent CAR-T therapyAugust 24, 2026 | globenewswire.comSee More Liminatus Pharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Liminatus Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Liminatus Pharma and other key companies, straight to your email. Email Address About Liminatus PharmaLiminatus Pharma (NASDAQ:LIMN) is a biopharmaceutical company focused on developing immunotherapies for cancer. Its research centers on targets in the tumor microenvironment that can interfere with the body’s immune response to cancer. The company’s lead program, LMP-001, is an antibody designed to target Galectin-9, an immune-regulating protein associated with tumor growth and immune suppression. Liminatus is also advancing a pipeline of cancer therapies based on its immuno-oncology research. The company’s work is focused on drug development rather than marketed products, and its programs are intended for potential use across cancer types. Publicly available information about its geographic reach and leadership is limited.View Liminatus Pharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 11/16 - 11/20If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel ItZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in LimboAirfares Are Up, Flights Are Tight: 3 Airline Stocks Facing a Winter TestOwens Corning's Stock Slump May Have a Silver Lining for Dividend InvestorsThe Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity StocksHard Drives Were Left for Dead, But Seagate and Western Digital Are Soaring Upcoming Earnings Hewlett Packard Enterprise (11/23/2026)Medtronic (11/24/2026)Analog Devices (11/24/2026)Autodesk (11/24/2026)Dell Technologies (11/24/2026)Deere & Company (11/25/2026)CrowdStrike (12/1/2026)Marvell Technology (12/1/2026)Bank Of Montreal (12/2/2026)Bank of Nova Scotia (12/2/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.